Trial Type: Gynecologic

LS-P-MAST
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Almhanna, Khaldoun
AGCT1532
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Protocol Status: OPEN TO ACCRUAL
Contact: DeNardo, Bradley
LS-P-FONTANA
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gynecologic, Thoracic
Contact: Khan, Hina
LS-P-CYCAD-1
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Trial Type: Breast, Gynecologic
Contact: Graff, Stephanie
SWOGS2205
Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
Protocol Status: OPEN TO ACCRUAL
Contact: Graff, Stephanie
LS-P-IMPACT
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Carneiro, Benedito
LS-P-MYTHIC
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Carneiro, Benedito